Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 2420564-02-7; 2420563-99-9
Drug Levels and Effects
Summary of Use during Lactation
The US FDA has withdrawn emergency-use authorization for tixagevimab and cilgavimab because of a lack of efficacy against some strains of SARS-CoV-2. These drugs are monoclonal antibodies directed against the SARS-CoV-2 virus that causes COVID-19 and used for prophylaxis in immune-compromised individuals. No information is available on their clinical use during breastfeeding. Because tixagevimab and cilgavimab are large protein molecules, the amount in milk is likely to be very low.[1] They are also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Until more data become available, tixagevimab and cilgavimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
- 2.
- Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
Substance Identification
Substance Name
Tixagevimab and Cilgavimab
CAS Registry Number
2420564-02-7; 2420563-99-9
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Sotrovimab.[Drugs and Lactation Database (...]Review Sotrovimab.. Drugs and Lactation Database (LactMed®). 2006
- Review Bebtelovimab.[Drugs and Lactation Database (...]Review Bebtelovimab.. Drugs and Lactation Database (LactMed®). 2006
- Review Bamlanivimab.[Drugs and Lactation Database (...]Review Bamlanivimab.. Drugs and Lactation Database (LactMed®). 2006
- Review Tixagevimab + Cilgavimab: First Approval.[Drugs. 2022]Review Tixagevimab + Cilgavimab: First Approval.Keam SJ. Drugs. 2022 Jun; 82(9):1001-1010.
- Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.[mBio. 2023]Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.Young-Xu Y, Epstein L, Marconi VC, Davey V, Korves C, Zwain G, Smith J, Cunningham F, Bonomo RA, Ginde AA. mBio. 2023 Aug 31; 14(4):e0102423. Epub 2023 Aug 3.
- Tixagevimab and Cilgavimab - Drugs and Lactation Database (LactMed®)Tixagevimab and Cilgavimab - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...